𝔖 Bobbio Scriptorium
✦   LIBER   ✦

RACK1: A superior independent predictor for poor clinical outcome in breast cancer

✍ Scribed by Xi-Xi Cao; Jing-Da Xu; Xiao-Li Liu; Jia-Wen Xu; Wen-Juan Wang; Qing-Quan Li; Qi Chen; Zu-De Xu; Xiu-Ping Liu

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
440 KB
Volume
127
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We aimed to investigate the expression of RACK1 in breast cancer, evaluate its role in predicting prognosis and compare with commonly used biomarkers: Ki67, ER, PR and HER‐2 for patients with breast cancer. The RACK1 expression and its clinical significance were examined in 160 breast carcinoma patients using immunohistochemistry. Correlations of RACK1 expression with other commonly used biomarkers and survival analyses were assessed. Immunohistochemistry results showed that the number of RACK1 cases scoring 0, 1, and 2 were 66, 54, and 40, respectively. RACK1 staining was strongly related to clinical stage, histological grade, Ki67, ER, PR and HER‐2 (all p < 0.05). Consistently, all of the cases exhibiting RACK1 staining score 0 were survivors, whereas the majority (55.0%) of those exhibiting RACK1 staining score 2 were deaths. Kaplan‐Meier survival analysis of 160 cases revealed a correlation between higher RACK1 expression levels and shorter overall survival times (p < 0.001). Univariate and multivariate analyses revealed that RACK1, tumor size, lymph node metastasis, and HER‐2 were independent prognostic factors (all p < 0.05). Interestingly, receiver operator characteristic (ROC) curves showed that the ROC areas for RACK1, Ki67, ER, PR and HER‐2 were 0.833, 0.766, 0.446, 0.387, and 0.689, respectively, and the superiority of RACK1 in sensitivity and specificity as biomarker was demonstrated. To our knowledge, it is the first time to investigate the expression of RACK1, and identified that RACK1 is a superior independent biomarker for diagnosis and prognosis comparing with currently widely used diagnostic index in breast carcinoma.

πŸ“œ SIMILAR VOLUMES

Overexpression of Id-1 is associated wit
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
✍ Sebastian F. Schoppmann; Monika Schindl; Guenther Bayer; Klaus Aumayr; Julia Die πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 427 KB πŸ‘ 1 views

## Abstract Id‐1 is an important regulator of cellular growth and differentiation and controls malignant progression of breast cancer cells. The aim of our study was to assess the clinical impact of Id‐1 expression in breast cancer, __i.e.__, its potential impact on prognosis and prediction of trea

C-Met overexpression in node-positive br
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
✍ Ernst Lengyel; Dieter Prechtel; James H. Resau; Katja Gauger; Anita Welk; Kristi πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 296 KB

Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n ‫؍‬ 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases a

Loss of trimethylation at lysine 27 of h
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers
✍ Yongkun Wei; Weiya Xia; Zhihong Zhang; Jinsong Liu; Huamin Wang; Nazmi V. Adsay; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 238 KB

## Abstract Methylation of lysine 27 on histone H3 (H3K27) by the EZH2 complex is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis in both breast and prostate cancers. However, the status of H3K27 methylation and its clinical